Citations

Clear

3314 citation(s) found for "Do, Alexander".

Peripheral nerve block anesthesia/analgesia for patients undergoing primary hip and knee arthroplasty: recommendations from the International Consensus on Anesthesia-Related Outcomes after Surgery (ICAROS) group based on a systematic review and meta-analys
Memtsoudis, Stavros G. , Cozowicz, Crispiana , Bekeris, Janis, Bekere, Dace, Liu, Jiabin , Soffin, Ellen M. , Mariano, Edward R. , Johnson, Rebecca L. , Go, George , Hargett, Mary J. , Lee, Bradley H. , Wendel, Pamela , Brouillette, Mark , Kim, Sang Jo, Baaklini, Lila , Wetmore, Douglas S., Hong, Genewoo , Goto, Rie , Jivanelli, Bridget , Athanassoglou, Vassilis , Αrgyra, Eriphili, Barrington, Michael J. , Borgeat, Alain , El‐Boghdadly, Kariem , Elkassabany, Nabil , Gautier, Philippe , Gerner, Peter, Valle, Alejandro González Della , Goytizolo, Enrique A. , Guo, Zhenggang , Hogg, Rosemary , Kehlet, Henrik , Kessler, Paul, Lavand"homme, Patricia, Macfarlane, Alan , McIsaac, Dan , Neal, Joseph M. , Peng, Philip , Pichler, Lukas, Poultsides, Lazaros, Sites, Brian D. , Stundner, Ottokar , Sun, Eric, Viscusi, Eugene R. , Votta‐Velis, E. Gina, YaDeau, Jacques T. , Sharrock, Nigel E. , Barrington, Michael John , El-Boghdadly, K , Elkassabany, Nabil M , Kopp, Sandra , Mantilla, Carlos, Neal, Joseph M , Poeran, Jashvant , Schwenk, Eric S , Stundner, Ottokar , Viscusi, Eugene , Wu, Christopher L , Mariano, Edward R , Johnson, Rebecca L , Soffin, Ellen M , Macfarlane, Alan James Robert , Andrés, José De , Kessler, Paul, Kopp, Sandra L. , Lavand"homme, Patricia, MacLean, Catherine H. , Mantilla, Carlos B. , McLawhorn, Alexander S. , Parks, Michael L. , Parvizi, Javad , Schwenk, Eric S.

Mayo Clinic

Regional Anesthesia & Pain Medicine | August 25, 2021 | Volume: 46 | Issue: 11 | Pages: 971-985

10.1136/rapm-2021-102750 | PMID 34433647 Get It

Background Evidence-based international expert consensus regarding the impact of peripheral nerve block (PNB) use in total hip/knee arthroplasty surgery. Methods A systematic review and meta-analysis: randomized controlled and observational studies investigating the impact of PNB utilization on major complications, including mortality, cardiac, pulmonary, gastrointestinal, renal, thromboembolic, neurologic, infectious, and bleeding complications. Medline, PubMed, Embase, and Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, were queried from 1946 to August 4, 2020. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess evidence quality and for the development of recommendations. Results Analysis of 122 studies revealed that PNB use (compared with no use) was associated with lower ORs for (OR with 95% CIs) for numerous complications (total hip and knee arthroplasties (THA/TKA), respectively): cognitive dysfunction (OR 0.30, 95% CI 0.17 to 0.53/OR 0.52, 95% CI 0.34 to 0.80), respiratory failure (OR 0.36, 95% CI 0.17 to 0.74/OR 0.37, 95% CI 0.18 to 0.75), cardiac complications (OR 0.84, 95% CI 0.76 to 0.93/OR 0.83, 95% CI 0.79 to 0.86), surgical site infections (OR 0.55 95% CI 0.47 to 0.64/OR 0.86 95% CI 0.80 to 0.91), thromboembolism (OR 0.74, 95% CI 0.58 to 0.96/OR 0.90, 95% CI 0.84 to 0.96) and blood transfusion (OR 0.84, 95% CI 0.83 to 0.86/OR 0.91, 95% CI 0.90 to 0.92). Conclusions Based on the current body of evidence, the consensus group recommends PNB use in THA/TKA for improved outcomes. Recommendation: PNB use is recommended for patients undergoing THA and TKA except when contraindications preclude their use. Furthermore, the alignment of provider skills and practice location resources needs to be ensured. Evidence level: moderate; recommendation: strong.
Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
Murugesan, Karthikeyan , Sharaf, Radwa , Montesion, Meagan , Moore, Jay A. , Pao, James , Pavlick, Dean C. , Upadhyay, Vivek , Alexander, Brian M. , Miller, Vincent A. , Javle, Milind , Bekaii‐Saab, Tanios , Albacker, Lee A. , Ali, Siraj M. , Bekaii Saab, Tanios S, Bekaii-Saab, Tanios S , Alexander, Brian M , Frampton, Garrett M. , Ross, Jeffrey S

Mayo Clinic

JCO Precision Oncology | August 19, 2021 | Volume: No volume available | Issue: 5 | Pages: 1285-1296

10.1200/po.20.00397 | PMID 34476330 Get It

PURPOSE Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare, aggressive primary liver carcinoma, with morphologic features of both hepatocellular carcinomas (HCC) and liver cholangiocarcinomas (CCA). METHODS The genomic profiles of 4,975 CCA, 1,470 HCC, and 73 cHCC-CCA cases arising from comprehensive genomic profiling in the course of clinical care were reviewed for genomic alterations (GA), tumor mutational burden, microsatellite instability status, genomic loss of heterozygosity, chromosomal aneuploidy, genomic ancestry, and hepatitis B virus status. RESULTS In cHCC-CCA, GA were most common in TP53 (65.8%), TERT (49.3%), and PTEN (9.6%), and 24.6% cHCC-CCA harbored potentially targetable GA. Other GA were predominantly associated with either HCC or CCA, including, but not limited to, TERT, FGFR2, IDH1, and presence of hepatitis B virus. On the basis of these features, a machine learning (ML) model was trained to classify a cHCC-CCA case as CCA-like or HCC-like. Of cHCC-CCA cases, 16% (12/73) were ML-classified as CCA-like and 58% (42/73) cHCC-CCA were ML-classified as HCC-like. The ML model classified more than 70% of cHCC-CCA as CCA-like or HCC-like on the basis of genomic profiles, without additional clinico-pathologic input. CONCLUSION These findings demonstrate the use of ML for classification as based on a targeted exome panel used during routine clinical care. Classification of cHCC-CCA by genomic features alone creates insights into the biology of the disease and warrants further investigation for relevance to clinical care.
Differences in management and treatment of traumatic adult pan brachial plexus injuries: a global perspective regarding continental variations
Shin, Alexander Y. , Desai, Ketan, Fox, Michael , Spinner, Robert J. , Shin, Alexander Y , Socolovsky, Mariano , Wang, Shufeng

Mayo Clinic

Journal of Hand Surgery (European Volume) | August 19, 2021 | Volume: 47 | Issue: 1 | Pages: 40-51

10.1177/17531934211039677 | PMID 34407694 Get It

An expert opinion study was designed to query five countries and six brachial plexus surgeons regarding the demographics, mechanisms of injury, evaluation, timing of surgery, reconstructive strategies and controversies in adult traumatic pan brachial plexus injuries. Variations in assessing outcomes, management of neuropathic pain and future considerations were elucidated. Clear differences in regional demographics, mechanisms of injury, patient evaluation and treatment strategies were identified. The role of phrenic nerve and contralateral C7 transfer, acute use of free functioning muscle transfers, root reimplantation and amputation/myoelectric prosthetic fitting were regional/surgeon dependent. Comparison of outcomes across regions requires an understanding of the regional nuances of patient demographics, injury mechanisms, preferred reconstructive strategies and how outcomes are measured. Future studies are required to allow accurate regional comparisons.
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers
Arora, Mansi , Abdelrahman, Amro M. , Alva‐Ruiz, Roberto, Leiting, Jennifer L. , Chen, Xianfeng , Usón, Pedro Luiz Serrano , Dumbauld, Chelsae, Baker, Alexander T. , Gamb, Scott I., Egan, Jan B. , Zhou, Yumei , Nagalo, Bolni Marius , Meurice, Nathalie , Eskelinen, Eeva‐Liisa , Braggio, Esteban , Barrett, Michael T. , Buetow, Kenneth H. , Roberts, Lewis R. , Bekaii‐Saab, Tanios , Ahn, Daniel H. , Truty, Mark J. , Bogenberger, James M. , Yonkus, Jennifer, Alva-Ruiz, Roberto, Leiting, Jennifer L , Serrano Uson Junior, Pedro Luiz, Dumbauld, Chelsae R, Salomao, Marcela A, Roberts, Lewis R , Braggio, Esteban , Uson, Pedro L S , Bekaii-Saab, Tanios S , Nagalo, Bolni , Baker, Alexander , Abdelrahman, Amro M , Yonkus, Jennifer A. , Salomao, Marcela , Kosiorek, Heidi , Sonbol, Mohamad Bassam , Mansfield, Aaron S. , Borad, Mitesh J.

Mayo Clinic

Hepatology | August 18, 2021 | Volume: 75 | Issue: 1 | Pages: 43-58

10.1002/hep.32102 | PMID 34407567 Get It

Abstract Background and aims Biliary tract cancers (BTCs) are uncommon, but highly lethal, gastrointestinal malignancies. Gemcitabine/cisplatin is a standard‐of‐care systemic therapy, but has a modest impact on survival and harbors toxicities, including myelosuppression, nephropathy, neuropathy, and ototoxicity. Whereas BTCs are characterized by aberrations activating the cyclinD1/cyclin‐dependent kinase (CDK)4/6/CDK inhibitor 2a/retinoblastoma pathway, clinical use of CDK4/6 inhibitors as monotherapy is limited by lack of validated biomarkers, diffident preclinical efficacy, and development of acquired drug resistance. Emerging studies have explored therapeutic strategies to enhance the antitumor efficacy of CDK4/6 inhibitors by the combination with chemotherapy regimens, but their mechanism of action remains elusive. Approach and results Here, we report in vitro and in vivo synergy in BTC models, showing enhanced efficacy, reduced toxicity, and better survival with a combination comprising gemcitabine/cisplatin and CDK4/6 inhibitors. Furthermore, we demonstrated that abemaciclib monotherapy had only modest efficacy attributable to autophagy‐induced resistance. Notably, triplet therapy was able to potentiate efficacy through elimination of the autophagic flux. Correspondingly, abemaciclib potentiated ribonucleotide reductase catalytic subunit M1 reduction, resulting in sensitization to gemcitabine. Conclusions As such, these data provide robust preclinical mechanistic evidence of synergy between gemcitabine/cisplatin and CDK4/6 inhibitors and delineate a path forward for translation of these findings to preliminary clinical studies in advanced BTC patients.
Mesenchymal stem cells and local tacrolimus delivery synergistically enhance neurite extension
Saffari, Sara , Saffari, Tiam M. , Chan, Katelyn, Shin, Alexander Y. , Chan, K. Ming , Shin, Alexander Y , Chan, Katelyn, Borschel, Gregory Howard

Mayo Clinic

Biotechnology and Bioengineering | August 16, 2021 | Volume: 118 | Issue: 11 | Pages: 4477-4487

10.1002/bit.27916 | PMID 34396506 Get It

AbstractBackgroundThe aim of this study was to investigate the combined effect of mesenchymal stem cells (MSC) and local delivery of tacrolimus (FK506) on nerve regeneration when applied to nerve autografts and decellularized allografts.MethodsA three‐dimensional in vitro compartmented cell culture system consisting of a neonatal dorsal root ganglion adjacent to a nerve graft was used to evaluate the regenerating neurites into the peripheral nerve scaffold. Nerve autografts and allografts were treated with (i) undifferentiated MSCs, (ii) FK506 (100 ng/mL) or (iii) both (N = 9/group). After 48 hours, neurite extension was measured to quantify nerve regeneration and stem cell viability was evaluated.ResultsStem cell viability was confirmed in all MSC‐treated grafts. Neurite extension was superior in autografts treated with FK506, and MSCs and FK506 combined (p < 0.001 and p = 0.0001, respectively), and autografts treated with MSCs (p = 0.12) were comparable to untreated autografts. In allografts, FK506 treatment and combined treatment were superior to controls (p < 0.001 and p = 0.0001, respectively), and treatment with MSCs (p = 0.09) was comparable to controls. All autograft groups were superior compared to their respective allograft treatment group (p < 0.05) in neurite extension.ConclusionsAlone, either MSC or FK506 treatment improved neurite outgrowth, and combined they further enhanced neurite extension in both autografts and allografts.
Three Cases of Emergency Department Medical Malpractice Involving “Consultations”: How Is Liability Legally Determined?
Aldalati, Alaa, Bellamkonda, Venkatesh R. , Finch, Alexander S. , Moore, Gregory P. , Moore, Gregory

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | August 14, 2021 | Volume: 5 | Issue: 3 | Pages: 283-288

10.5811/cpcem.2021.7.52680 | PMID 34437032 Get It

This article presents three successfully litigated medical malpractice cases involving emergency physicians and consultants. We discuss the respective case medical diagnoses, as well as established legal principles that determine in a court proceeding which provider will be liable. Specifically, we explain the legal principles of “patient physician relationship” and “affirmative act.”
Multimodal platform for assessing drug distribution and response in clinical trials
Lopez, Begoña G C, Kohale, Ishwar N. , Du, Ziming , Korsunsky, Ilya , Dai, Yang , Gaglia, Giorgio , Randall, Elizabeth C., Clark, Amanda R. , Marin, Bianca M. , Mladek, Ann C. , Agar, Jeffrey N. , Supko, Jeffrey G. , Wen, Patrick Y. , Lee, Eudocia Q. , Agar, Nathalie Y.R. , Marin, Bianca-Maria, Burgenske, Danielle M. , Grossman, Stuart A , Santagata, Sandro , Sarkaria, Jann, Agar, Nathalie Y R , Marin, Bianca M , Mladek, Ann C , Lopez, Begoña G C, Abdelmoula, Walid M. , Stopka, Sylwia A. , Regan, Michael S. , Basu, Sankha S. , Grossman, Stuart A. , Nabors, Burt , Raychaudhuri, Soumya , Ligon, Keith L , Wen, Patrick Yung , Alexander, Brian M. , Sarkaria, Jann N. , White, Forest M.

Mayo Clinic

Neuro-Oncology | August 11, 2021 | Volume: 24 | Issue: 1 | Pages: 64-77

10.1093/neuonc/noab197 | PMID 34383057 Get It

Abstract Background Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. Methods Patient-derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee1 inhibitor, and tissue drug distribution was measured with MALDI-MSI. Phosphoproteomics was measured in the same tumors to identify biomarkers of drug target engagement and cellular adaptive response. Multiplexed tissue imaging was performed on sister sections to evaluate spatial co-localization of drug and cellular response. The integrated platform was then applied on clinical specimens from glioblastoma patients enrolled in the phase 1 clinical trial. Results PDX tumors exposed to different doses of adavosertib revealed intra- and inter-tumoral heterogeneity of drug distribution and integration of the heterogeneous drug distribution with phosphoproteomics and multiplexed tissue imaging revealed new markers of molecular response to adavosertib. Analysis of paired clinical specimens from patients enrolled in the phase 1 clinical trial informed the translational potential of the identified biomarkers in studying patient’s response to adavosertib. Conclusions The multimodal platform identified a signature of drug efficacy and patient-specific adaptive responses applicable to preclinical and clinical drug development. The information generated by the approach may inform mechanisms of success and failure in future early phase clinical trials, providing information for optimizing clinical trial design and guiding future application into clinical practice.
Prognostic implications of left heart diastolic dysfunction in adults with coarctation of aorta
Egbe, Alexander C. , Miranda, William R. , Oh, Jae K. , Connolly, Heidi M.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | August 8, 2021 | Volume: 22 | Issue: 11 | Pages: 1332-1340

10.1093/ehjci/jeab165 | PMID 34423358 Get It

AbstractAimsThe prognostic implication of left atrial (LA) dysfunction and left ventricular diastolic dysfunction (LVDD) in patients with coarctation of aorta (COA) is unknown. The purpose of this study was to determine whether LA dysfunction and LVDD were associated with mortality in COA patients.Methods and resultsThis is a retrospective review of adults (age ≥18 years) with repaired COA that underwent transthoracic echocardiogram (2000–18). LVDD was determined using the 2016 guidelines for LV diastolic function assessment, and LA dysfunction was assessed using LA reservoir strain. Of 721 patients, LV diastolic function could be determined in 635 (88%); and 414 (65%) had no LVDD, while 146 (23%), 53 (8%), and 22 (4%) had Grade I/II/III LVDD, respectively. The mean LA reservoir strain was 39 ± 11%, and patients were divided into quartiles: top quartile (reference group), mild LA dysfunction, moderate LA dysfunction, and severe LA dysfunction. Grade III LVDD (but not Grades I and II) was associated with death/transplant. On the other hand, there was an incremental risk of death/transplant across LA strain quartiles: mild LA dysfunction [hazard ratio (HR) 1.16, 1.04–2.06], moderate LA dysfunction (HR 1.75, 1.27–3.58), and severe LA dysfunction (HR 3.49, 1.88–7.16). Of 86 patients with indeterminate diastolic function, there was a trend towards a lower 5-year transplant-free survival in patients with LA dysfunction vs. normal LA function (83% vs. 91%, P = 0.06).ConclusionLA dysfunction (but not LVDD) was associated with incremental risk of mortality and thus can be used for prognostication in all patients including those with indeterminate diastolic function.
In vivo human gracilis whole-muscle passive stress–sarcomere strain relationship
Persad, Lomas S. , Binder‐Markey, Benjamin I. , Lieber, Richard L. , Lieber, Richard L , Shin, Alexander Y. , Kaufman, Kenton R.

Mayo Clinic

Journal of Experimental Biology | August 6, 2021 | Volume: 224 | Issue: 17 | Pages: No page available

10.1242/jeb.242722 | PMID 34355750 Get It

ABSTRACT We measured the passive mechanical properties of intact, living human gracilis muscles (n=11 individuals, 10 male and 1 female, age: 33±12 years, mass: 89±23 kg, height: 177±8 cm). Measurements were performed in patients undergoing surgery for free-functioning myocutaneous tissue transfer of the gracilis muscle to restore elbow flexion after brachial plexus injury. Whole-muscle force of the gracilis tendon was measured in four joint configurations (JC1–JC4) with a buckle force transducer placed at the distal tendon. Sarcomere length was also measured by biopsy from the proximal gracilis muscle. After the muscle was removed, a three-dimensional volumetric reconstruction of the muscle was created via photogrammetry. Muscle length from JC1 to JC4 increased by 3.3±1.0, 7.7±1.2, 10.5±1.3 and 13.4±1.2 cm, respectively, corresponding to 15%, 34%, 46% and 59% muscle fiber strain, respectively. Muscle volume and an average optimal fiber length of 23.1±0.7 cm yielded an average muscle physiological cross-sectional area of 6.8±0.7 cm2 which is approximately 3 times that measured previously from cadaveric specimens. Absolute passive tension increased from 0.90±0.21 N in JC1 to 16.50±2.64 N in JC4. As expected, sarcomere length also increased from 3.24±0.08 µm at JC1 to 3.63±0.07 µm at JC4, which are on the descending limb of the human sarcomere length–tension curve. Peak passive muscle stress was 27.8±5.5 kPa in JC4 and muscle modulus ranged from 44.8 MPa in JC1 to 125.7 MPa in JC4. Comparison with other mammalian species indicates that human muscle passive mechanical properties are more similar to rodent muscle than to rabbit muscle. These data provide direct measurements of whole-human muscle passive mechanical properties that can be used in modeling studies and for understanding comparative passive mechanical properties among mammalian muscles.